Cell Biotech Co

Cell Biotech Co Debt/EBITDA

The Total Debt to EBITDA Ratio of Cell Biotech Co (049960.KQ) as of Oct 15, 2026 is 0.04. In the previous year, Total Debt to EBITDA Ratio was 0.20 — a change of -80.07% (lower).

Debt/EBITDA

0.04

YoY

-80.07%

Last updated:

Total Debt to EBITDA Ratio of Cell Biotech Co is 2024 0.04 . Total Debt to EBITDA Ratio of Cell Biotech Co was 2023 0.20 . It decreases by -80.07% lower compared to the previous year.

The Cell Biotech Co Debt/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt/EBITDA
Date
Debt/EBITDA
Jan 1, 2017
0.00 KRW
Jan 1, 2018
0.00 KRW
Jan 1, 2019
0.07 KRW
Jan 1, 2020
0.11 KRW
Jan 1, 2021
0.04 KRW
Jan 1, 2022
0.04 KRW
Jan 1, 2023
0.20 KRW
Jan 1, 2024
0.04 KRW
The Cell Biotech Co Debt/EBITDA history
YEARDebt/EBITDAYoY
0.04-80.07%
0.20+370.31%
0.04-3.95%
0.04-61.37%
0.11+61.81%
0.07—
0.00—
0.00—
0.00—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cell Biotech Co Stock analysis

What does Cell Biotech Co do? Cell Biotech Co Ltd is a South Korean company based in Gimpo, Gyeonggi-Do, operating within the Health Care sector, specifically in the Biotechnology industry. The company went public through an IPO on December 13, 2002. Its primary focus is on the research, development, and manufacturing of probiotics, particularly lactobacillus-based products. Cell Biotech produces lactic acid bacteria (LAB) powders, which serve as raw materials for foods and medicines aimed at enhancing immunity and improving digestion. Additionally, the company develops finished products containing LABs, designed for applications such as intestinal health improvement, carcinogen inhibition, and calcium supplementation. These products are distributed both domestically within South Korea and internationally. The company's website is http://www.cellbiotech.com/, providing further information about its operations and offerings. Cell Biotech's activities are centered around biotechnology solutions that support health and wellness through probiotic applications. The firm operates with a focus on research and development to advance its product lines, though specific details about its research initiatives or product names beyond the mentioned categories are not provided. The company's market presence spans both domestic and international channels, reflecting its commitment to delivering probiotic-based health solutions across various markets. Cell Biotech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cell Biotech Co stock

Total Debt to EBITDA Ratio of Cell Biotech Co is 0.04 in 2024.

Total Debt to EBITDA Ratio of Cell Biotech Co changed from 0.20 to 0.04, representing a -80.07% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Total Debt to EBITDA Ratio Cell Biotech Co since 2006 – with annual values, charts, and detailed analysis.

Debt/EBITDA measures total debt relative to earnings before interest, taxes, depreciation, and amortization. It indicates the years needed to repay all debt from EBITDA.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Total Debt to EBITDA Ratio's Cell Biotech Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Leverage — Cell Biotech Co

Debt-to-EquityNet Debt / EBITDAInterest CoverageCurrent RatioQuick RatioCash RatioDebt / AssetsFinancial LeverageEquity RatioLT Debt/EquityNet Debt/EquityDebt/EBITDADSCRFinancial Debt RatioOCF/DebtFCF/DebtNet Debt/FCFDebt/Market Cap

All Key Metrics — Cell Biotech Co